Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock
Amy S. Broidrick, insider at Qualigen Therapeutics
Amy S. Broidrick Insider Alerts

Get notified the next time Amy S. Broidrick buys or sells Qualigen Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Amy S. Broidrick Insider Information

Ms. Broidrick held key roles in the successful worldwide launches and life cycle marketing of blockbuster drugs including Zetia™, VYTORIN™, and Celebrex™, and specialty brands. Since 2016, she served as Senior Vice President, Head of Corporate Development at Viking Therapeutics, responsible for building and implementing the US and global corporate and business development functions. Before that, she was Vice President, Head of Global Marketing Excellence and Business Innovation with EMD Serono, Inc, part of Merck KGaA (Germany), where she led global and country brand and launch planning, and strategic transformation initiatives. Ms. Broidrick was Vice President, Head of Marketing and Commercialization at Arena Pharmaceuticals, where she oversaw commercialization planning for a first-in-class obesity drug, and also led Portfolio Planning. Before Arena, she held roles of increasing responsibility at Merck & Co. and Pfizer (formerly GD Searle) including Global Brand Leader with P&L accountability. She led Merck & Co.’s new products marketing planning across brands and pipeline for the Asia Pacific region. Ms. Broidrick holds a BA from Fairleigh Dickinson University, completed further undergraduate studies at Wroxton College in England, and performed post-graduate work at Fairleigh Dickinson.

What is Amy S. Broidrick's net worth?

The estimated net worth of Amy S. Broidrick is at least $7,110.00 as of April 26th, 2021. Ms. Broidrick owns 4,500 shares of Qualigen Therapeutics stock worth more than $7,110 as of November 30th. This net worth evaluation does not reflect any other assets that Ms. Broidrick may own. Learn More.

What is Amy S. Broidrick's salary?

As the EVP of Qualigen Therapeutics, Inc., Ms. Broidrick earned a total compensation package of $645,406.00 in 2020. Ms. Broidrick earned a salary of $41,837.00, options awards of $603,569.00, and no other miscellaneous compensation.

How do I contact Amy S. Broidrick?

The corporate mailing address for Ms. Broidrick and other Qualigen Therapeutics executives is 2042 Corte Del Nogal, Carlsbad CA, 92011. Qualigen Therapeutics can also be reached via phone at (310) 203-1000 and via email at [email protected]

Has Amy S. Broidrick been buying or selling shares of Qualigen Therapeutics?

Amy S. Broidrick has not been actively trading shares of Qualigen Therapeutics during the past quarter. Most recently, on Monday, April 26th, Amy S. Broidrick bought 4,500 shares of Qualigen Therapeutics stock. The stock was acquired at an average cost of $2.03 per share, with a total value of $9,135.00. Following the completion of the transaction, the executive vice president now directly owns 4,500 shares of the company's stock, valued at $9,135.

Who are Qualigen Therapeutics' active insiders?

Qualigen Therapeutics' insider roster includes Amy Broidrick (EVP), Kurt Kruger (Director), and Michael Poirier (CEO).

Are insiders buying or selling shares of Qualigen Therapeutics?

During the last year, Qualigen Therapeutics insiders bought shares 5 times. They purchased a total of 30,205 shares worth more than $55,566.00. The most recent insider tranaction occured on August, 19th when Director Kurt H. Kruger bought 8,000 shares worth more than $9,840.00. Insiders at Qualigen Therapeutics own 4.7 % of the company.

Information on this page was last updated on 8/19/2021.

Amy S. Broidrick Insider Trading History at Qualigen Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/26/2021Buy4,500$2.03$9,135.004,500View SEC Filing Icon  
See Full Table

Amy S. Broidrick Buying and Selling Activity at Qualigen Therapeutics

This chart shows Amy S Broidrick's buying and selling at Qualigen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Qualigen Therapeutics Company Overview

Qualigen Therapeutics logo
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.
Read More

Today's Range

Now: $1.58
Low: $1.55
High: $2.97

50 Day Range

MA: $1.31
Low: $0.94
High: $2.56

2 Week Range

Now: $1.58
Low: $0.93
High: $4.66


81,985,284 shs

Average Volume

2,472,137 shs

Market Capitalization

$46.00 million

P/E Ratio


Dividend Yield



Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Put this company on your investing radar today.